Galapagos ADRs Down After Study Data
15 Juillet 2021 - 5:59PM
Dow Jones News
By Michael Dabaie
Galapagos NV ADRs were down 13% to $57.40 after reporting data
from several studies.
The Belgium-based biotechnology company said it had positive
topline results with tyrosine kinase 2 inhibitor GLPG3667 in a
Phase 1b study in psoriasis. The company said the study showed
positive efficacy signal at week 4 and the data support initiation
of Phase 2b dose finding study in psoriasis.
Galapagos also reported topline results with salt inducible
kinase 2/3 inhibitor GLPG3970 in three patient studies. These were
a Phase 1b study in moderate to severe psoriasis and two Phase 2a
studies in moderate to severely active ulcerative colitis and
rheumatoid arthritis.
The study in psoriasis patients showed improvement in Psoriasis
Area and Severity Index score at Week 6.
The study in ulcerative colitis patients shows signs of
"biologically important effects," but these findings didn't
translate in a differentiation from placebo on change from baseline
total Mayo Clinic Score, the company said.
In the rheumatoid arthritis study, at week 6 patients on
GLPG3970 showed no differentiation from placebo on the majority of
efficacy endpoints, Galapagos said.
"The data will be presented with greater detail during the 2Q21
earnings call, but based upon the initial data disclosed, it seems
likely that both the GLPG3970 and GLPG3667 programs will move into
the next phase of clinical studies for psoriasis, respectively,"
Raymond James said in a note.
J.P. Morgan called the GLPG3667 "data somewhat encouraging, if
undifferentiated," and said the GLPG3970 data was disappointing.
"We believe the net of these two updates is negative," the firm
said in an analyst note.
"On the basis of the data reported last night, we believe
expectations for GLPG's TYK2 could be slightly increased, as the
asset looks at least broadly in the same ballpark as [Bristol Myers
Squibb's] far more advanced TYK2. However, we see potential for
even heavily risk-adjusted SIK2/3 forecasts taken out of models,
given failure of the lead asset, with the company now needing to
take a follow-on into new clinical trials," J.P. Morgan said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 15, 2021 11:48 ET (15:48 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Galapagos (EU:GLPG)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Galapagos (EU:GLPG)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024